Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response
Frontiers in Cell and Developmental Biology · 24.06.2026 · 14
DOI: 10.3389/fcell.2026.1844017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 24.06.2026. Verfasst von Qiuyu Mo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
The progression of acute myeloid leukemia (AML) is characterized by intricate interactions between leukemia cells and the bone marrow (BM) microenvironment.
Methods
In this study, we conducted a comprehensive analysis of the plasma cytokine composition in BM samples from patients with AML. A total of 75 BM samples were collected from AML patients consecutively recruited, including 41 newly diagnosed (ND‐AML), 19 complete remission (CR) and 15 relapsed/refractory cases (R/R-AML). Using enzyme-linked immunoadsorbent assay, we analyzed BM plasma levels of interleukin (IL)-1 family (IL-1β, IL-1RA and IL-18), IL-2 family (IL-2, IL-4, IL-13, IL-15 and IL-21), IL-12, interferon-gamma (IFN-γ), innate inflammatory and immune regulatory cytokines [IL-6, IL-10, IL-17, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β].
Results
Our study found significant differences in BM plasma inflammatory and immunologic cytokines between ND-AML, CR, and R/R-AML, with notable changes in LDH, ELN risk, IL-12, IL-18, and IL-21 between incomplete remission (ICR) and CR status. These cytokines were at weakened level in the BM microenvironment of R/R-AML. Concentrations of IL-17 and TGF-β in BM plasma elevated at initial diagnosis, declined after CR, and increased again at relapse, indicating the disease activity.
Conclusion
These findings emphasize the dynamic monitoring of BM plasma cytokines during AML progression, and highlight the significance of cytokine composition in guiding treatment and improving patient outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
- Department of Hematology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, China.
- Department of Hematology, Hunan Provincial People's Hospital and The First Affiliated Hospital of Hunan Normal University, Changsha, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Mo, Q., Xie, G., Huang, K., Nie, W., Chen, H., Yang, J., Liu, C., Su, X., Ning, Q., Chang, J., & Jiang, D. (2026). Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response. Frontiers in Cell and Developmental Biology, 14. https://doi.org/10.3389/fcell.2026.1844017
Vancouver
Mo Q, Xie G, Huang K, Nie W, Chen H, Yang J, et al. Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response. Frontiers in Cell and Developmental Biology. 2026;14. doi:10.3389/fcell.2026.1844017
BibTeX
@article{Mo2026,
author = {Mo, Qiuyu and Xie, Guoran and Huang, Kangle and Nie, Weiye and Chen, Hong and Yang, Jie and Liu, Chang and Su, Xiayun and Ning, Qunqian and Chang, Jie and Jiang, Duanfeng},
title = {Bone marrow plasma cytokine composition indicates acute myeloid leukemia progression and treatment response},
journal = {Frontiers in Cell and Developmental Biology},
year = {2026},
volume = {14},
doi = {10.3389/fcell.2026.1844017}
}
EUVIMED